조사회사 : MarketsandMarkets (마켓츠앤마켓츠) 출판년월 : 2024년07월
GLP-1 Analogues Market – Global Forecast to 2032
GLP-1 유사체 시장 – 제품(오젠픽, 리베르사스, 삭센다, 우고비, 만자로, 젬바운드, 빅토자, 톨리시티), 형식(단일 투여, 다중 투여, 정제), ROA(피하, 경구), 적응증(당뇨병, 비만) – 2032년까지 세계 예측
GLP-1 Analogues Market by Product (Ozempic, Rybelsus, Saxenda, Wegovy, Mounjaro, Zepbound, Victoza, Trulicity), Format (Single dose, Multi-dose, Tablets), ROA (Subcutaneous, Oral), Indication (Diabetes, Obesity) – Global Forecast to 2032
| 페이지 수 | 316 |
| 도표 수 | 364 |
| 가격 | |
| Single User License | USD 4,950 |
| Multi User License | USD 6,650 |
| Corporate License | USD 8,150 |
| Enterprise License | USD 10.000 |
| 구성 | 영문조사보고서 |
Report Overview
The GLP-1 Analogues market is expected to reach USD 471.1 billion by 2032 from USD 47.4 billion in 2024, at a CAGR of 33.2% during the forecast period.
GLP-1 유사체 시장은 예측 기간 동안 33.2%의 CAGR로 2024년 474억 달러에서 2032년까지 4,711억 달러에 이를 것으로 예상됩니다.
The key factors driving the growth of the GLP-1 Analogues market include the growing popularity of the GLP-1 drug class for the treatment of chronic obesity and weight management and high efficacy of GLP-1 analogues for treating type 2 diabetes. Additionally, innovation focusing on the development of convenient forms of GLP-1 drugs, such as oral dosage forms and single dose autoinjectors, are expected to drive growth of GLP-1 analogues market.
The GLP-1 Analogues market has been segmented based on products, format, route of administration, indication, and end-user.
“By product, Zepbound (tirzepatide) drug is forecasted to grow at the fastest rate in the GLP-1 Analogues market”
Based on product, the GLP-1 Analogues market is categorized into Ozempic (semaglutide), Trulicity (dulaglutide), Mounjaro (tirzepatide), Wegovy (semaglutide), Rybelsus (semaglutide), Saxenda (liraglutide [rDNA origin] injection), Victoza (liraglutide), Xultophy 100/3.6 (insulin degludec and liraglutide injection), Soliqua 100/33 (insulin glargine and lixisenatide injection), Zepbound (tirzepatide), Bydureon (exenatide extended-release), and other products. Zepbound is expected to experience fastest growth during the forecast period owing to factors such as approval of the drug for the treatment of obesity, exponential revenue growth observed since launch of the drug in 2023, and growing adoption of tirzepatide for obesity and weight management.
“By product format, the single dose format segment accounted for the largest share in the GLP-1 Analogues market”
Based on product format, the GLP-1 Analogues market is segmented into single-dose, multi-dose, and tablets. In 2023, the single-dose format segment accounted for the largest share of the GLP-1 Analogues market. Growth in this market segment can be attributed to the ease of administration and lower injection frequencies offered by single-dose format, together with the growing availability of single-dose auto-injectors.
“North America: accounted for the largest share of the GLP-1 Analogues market”
North America accounted for the largest share of the GLP-1 Analogues market. The large share of the North American region can be attributed to growing investments and funding in biomedical research by government bodies and pharmaceutical & biotechnology companies. Early adoption of emerging technologies and alternative therapies, supported by the availability of the majority of GLP-1 products in the region, further supports market growth. Also, a strong established presence of several market players in the region is another key factor supporting market growth. These key companies include Eli Lilly and Company (US), Novo Nordisk A/S (Denmark).
“Europe: The second-largest region in the GLP-1 Analogues market.”
The Europe GLP-1 Analogues market is the second largest market for GLP-1 Analogue drugs. This is attributed to the presence of a large number of academic and research institutes in this region, growing investments by market players and government institutes, and an increasing focus on research and development activities.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70% and Demand Side 30%
- By Designation: Managers – 45%, Directors- 30%, and Executives – 25%
- By Country: North America- 40%, Europe- 30%, Asia Pacific- 20%, Latin America- 5%, and Middle East and Africa- 5%
Prominent Players
Novo Nordisk A/S (Denmark), Eli Lilly and Company (US), Sanofi (France), AstraZeneca (UK), Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (China), Boehringer Ingelheim International GmbH (Germany), Innovent (China), Paige Biopharmaceutical (Suzhou) Co., Ltd. (China), Sciwind Biosciences Co., Ltd. (China), Zealand Pharma A/S (Denmark), Beijing Dongfang Baitai Biotechnology Co., Ltd (China), and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (China)
Research Coverage:
This report provides a detailed picture of the GLP-1 Analogues market. It aims to estimate the size and future growth potential of the market across different segments, such as the product, product format, route of administration, indication, end user, and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders and new entrants by providing them with the closest approximations of the revenue numbers for the GLP-1 Analogues market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
The report provides insights on the following pointers”
- Analysis of key drivers (Strong R&D pipeline, Improved relative efficacy of GLP-1 drugs), opportunities (Integration of GLP-1 drugs into telehealth and digital weight management programs), restraints (High barriers for new entrants due to duopoly), and challenges (Off-label use of GLP-1 drugs, High non-adherence to therapy after 12-24 months) influencing the growth of the GLP-1 Analogues market.
- Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the GLP-1 Analogues market.
- Market Development: Comprehensive information about lucrative markets- the report analyses the GLP-1 Analogues market across varied regions.
- Market Diversification: Exhaustive information about new drugs, untapped geographies, recent developments, and investments in the GLP-1 Analogues market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the GLP-1 analogues market.
Table of Contents
1 INTRODUCTION 29
1.1 STUDY OBJECTIVES 29
1.2 MARKET DEFINITION 29
1.2.1 INCLUSIONS & EXCLUSIONS 29
1.3 MARKET SCOPE 30
1.3.1 MARKETS COVERED 30
1.3.2 REGIONS COVERED 30
1.3.3 YEARS CONSIDERED 31
1.3.4 CURRENCY CONSIDERED 31
1.4 STAKEHOLDERS 31
1.5 RECESSION IMPACT 32
2 RESEARCH METHODOLOGY 33
2.1 RESEARCH DATA 33
2.1.1 SECONDARY DATA 34
2.1.2 PRIMARY DATA 34
2.2 MARKET SIZE ESTIMATION 35
2.2.1 MARKET SIZE ASSESSMENT 38
2.3 MARKET GROWTH FORECAST 39
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 41
2.5 STUDY ASSUMPTIONS 42
2.6 LIMITATIONS 42
2.7 RISK ANALYSIS 42
2.8 RECESSION IMPACT ANALYSIS 43
3 EXECUTIVE SUMMARY 44
4 PREMIUM INSIGHTS 48
4.1 GLP-1 ANALOGUES MARKET OVERVIEW 48
4.2 NORTH AMERICA: GLP-1 ANALOGUES MARKET SHARE,
BY INDICATION AND COUNTRY (2023) 49
4.3 GLP-1 ANALOGUES MARKET SHARE, BY PRODUCT, 2024 VS. 2032 50
4.4 GLP-1 ANALOGUES MARKET SHARE, BY INDICATION, 2023 51
4.5 GLP-1 ANALOGUES MARKET SHARE, BY END USER, 2024 VS. 2032 51
4.6 GLP-1 ANALOGUES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 52
5 MARKET OVERVIEW 53
5.1 INTRODUCTION 53
5.2 MARKET DYNAMICS 53
5.2.1 DRIVERS 54
5.2.1.1 Strong R&D pipeline 54
5.2.1.2 Improved relative efficacy of GLP-1 drugs 55
5.2.1.3 High demand, expanding insurance coverage, growing sales, increasing awareness, and positive outcomes 56
5.2.2 RESTRAINTS 56
5.2.2.1 High barriers for new entrants due to duopoly 56
5.2.3 OPPORTUNITIES 57
5.2.3.1 Extended therapeutic uses 57
5.2.3.2 Integration of GLP-1 drugs into telehealth and digital weight management programs 58
5.2.4 CHALLENGES 59
5.2.4.1 Off-label use of GLP-1 drugs 59
5.2.4.2 High non-adherence to therapy after 12–24 months 59
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 59
5.4 PRICING ANALYSIS 60
5.4.1 AVERAGE SELLING PRICE TREND OF GLP-1 ANALOGUES 60
5.4.2 AVERAGE SELLING PRICES OF TOP GLP-1 ANALOGUES, BY COUNTRY/REGION 61
5.5 TECHNOLOGY ANALYSIS 63
5.5.1 KEY TECHNOLOGIES 63
5.5.1.1 Chemical Synthesis 63
5.5.1.2 Recombinant DNA Technology 64
5.5.2 ADJACENT TECHNOLOGIES 64
5.5.2.1 Hydrogel Depot Technology 64
5.5.2.2 Technologies for oral delivery of GLP-1 analogues 64
5.6 PIPELINE ANALYSIS 66
5.7 TRADE DATA 73
5.8 PATENT ANALYSIS 73
5.8.1 METHODOLOGY 73
5.8.2 INNOVATION AND PATENT APPLICATIONS 74
5.8.3 TOP APPLICANTS 74
5.9 VALUE CHAIN ANALYSIS 76
5.10 SUPPLY CHAIN ANALYSIS 78
5.11 ECOSYSTEM ANALYSIS 79
5.11.1 GLP-1 ANALOGUES MARKET: ROLE OF RAW MATERIAL VENDORS 79
5.11.2 GLP-1 ANALOGUES MARKET: ROLE OF PRODUCT PROVIDERS AND
PHASE 3 PIPELINE PRODUCT COMPANIES 80
5.11.3 GLP-1 ANALOGUES MARKET: ROLE OF END USERS 80
5.11.4 GLP-1 ANALOGUES MARKET: ROLE OF REGULATORY AUTHORITIES 81
5.12 PORTER’S FIVE FORCES ANALYSIS 81
5.12.1 THREAT OF NEW ENTRANTS 82
5.12.2 THREAT OF SUBSTITUTES 82
5.12.3 BARGAINING POWER OF SUPPLIERS 82
5.12.4 BARGAINING POWER OF BUYERS 83
5.12.5 INTENSITY OF COMPETITIVE RIVALRY 83
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 83
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 83
5.13.2 BUYING CRITERIA FOR GLP-1 ANALOGUES 84
5.14 REGULATORY LANDSCAPE 85
5.14.1 REGULATORY SCENARIO 85
5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 86
5.14.2.1 North America 86
5.14.2.2 Europe 86
5.14.2.3 Asia Pacific 87
5.14.2.4 Rest of the World 88
5.15 KEY CONFERENCES & EVENTS, 2024–2025 88
5.16 CASE STUDIES 89
5.16.1 STUDY OF TIRZEPATIDE AS A CASE IN GLP-1 DRUGS MARKET 89
5.16.2 OZEMPIC OFF-LABEL USE 90
5.17 INVESTMENT AND FUNDING SCENARIO 90
6 GLP-1 ANALOGUES MARKET, BY PRODUCT 91
6.1 INTRODUCTIONS 92
6.2 OZEMPIC 93
6.2.1 RISING ADOPTION TO SUPPORT MARKET GROWTH 93
6.3 TRULICITY 95
6.3.1 COMPETITOR REVENUE GROWTH TO AFFECT GROWTH 95
6.4 MOUNJARO 98
6.4.1 EXPONENTIAL GROWTH ANTICIPATED DUE TO HIGH ADOPTION
IN NORTH AMERICA 98
6.5 WEGOVY 101
6.5.1 INCREASING USE FOR WEIGHT MANAGEMENT TO SUPPORT GROWTH 101
6.6 RYBELSUS 104
6.6.1 CONVENIENCE OF ORAL ADMINISTRATION TO DRIVE MARKET 104
6.7 SAXENDA 106
6.7.1 DEVELOPMENT OF GENERIC VERSIONS TO SLOW GROWTH 106
6.8 VICTOZA 109
6.8.1 ADOPTION OF ORAL GLP-1S TO RESTRAIN MARKET GROWTH 109
6.9 XULTOPHY 111
6.9.1 REGULATORY APPROVALS TO SUPPORT MARKET GROWTH 111
6.10 SOLIQUA 112
6.10.1 COMPETITOR GLP-1 PRODUCTS THREAT TO GROWTH 112
6.11 ZEPBOUND 113
6.11.1 STRONG REVENUE GROWTH TO ENSURE CONTINUED PRESENCE 113
6.12 BYDUREON 116
6.12.1 COMPETITOR PRODUCTS TO AFFECT MARKET GROWTH 116
6.13 OTHER PRODUCTS 116
7 GLP-1 ANALOGUES MARKET, BY FORMAT 118
7.1 INTRODUCTIONS 119
7.2 SINGLE DOSE 119
7.2.1 HIGH ADOPTION DUE TO EASE OF ADMINISTRATION TO SUPPORT GROWTH 119
7.3 MULTI-DOSE 122
7.3.1 LOW COST TO ATTRACT LARGER ADOPTION 122
7.4 TABLETS 125
7.4.1 DEVELOPMENT OF HIGH-POTENCY GLP-1S TO SUPPORT MARKET GROWTH 125
8 GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION 128
8.1 INTRODUCTION 129
8.2 SUBCUTANEOUS ADMINISTRATION 129
8.2.1 PEN INJECTORS 133
8.2.1.1 Ease of monitoring to support adoption 133
8.2.2 AUTOINJECTORS 136
8.2.2.1 Advantages offered over pen injectors to support adoption 136
8.3 ORAL ADMINISTRATION 139
8.3.1 ELIMINATION OF NEEDLE PHOBIA AND EASE OF USE TO DRIVE COMPLIANCE 139
9 GLP-1 ANALOGUES MARKET, BY INDICATION 142
9.1 INTRODUCTION 143
9.2 DIABETES 143
9.2.1 HIGH EFFICACY TO SUPPORT MARKET GROWTH 143
9.3 OBESITY 146
9.3.1 INCREASING DEMAND AND PIPELINE FOCUS ON ANTI-OBESITY GLP-1S TO DRIVE MARKET 146
9.4 OTHER INDICATIONS 149
10 GLP-1 ANALOGUES MARKET, BY END USER 152
10.1 INTRODUCTIONS 153
10.2 HOME CARE SETTINGS 153
10.2.1 RISING NUMBER OF TELEHEALTH COMPANIES AND CONVENIENCE OF HOME CARE TO SUPPORT MARKET GROWTH 153
10.3 LONG-TERM CARE FACILITIES 156
10.3.1 GROWING GERIATRIC POPULATION AND RISING CHRONIC DISEASE INCIDENCE TO DRIVE MARKET 156
10.4 HOSPITALS & SPECIALTY CLINICS 159
10.4.1 ADOPTION OF GLP-1 FOR VARIED INDICATIONS TO SUPPORT MARKET GROWTH 159
11 GLP-1 ANALOGUES MARKET, BY REGION 163
11.1 INTRODUCTION 164
11.2 NORTH AMERICA 164
11.2.1 NORTH AMERICA: RECESSION IMPACT 165
11.2.2 US 168
11.2.2.1 Strategic developments by major players and R&D activities to drive market 168
11.2.3 CANADA 171
11.2.3.1 Strong research infrastructure and availability of funding to support market growth 171
11.3 EUROPE 174
11.3.1 EUROPE: RECESSION IMPACT 174
11.3.2 GERMANY 179
11.3.2.1 Improving accessibility to support market growth in Germany 179
11.3.3 UK 181
11.3.3.1 Increasing research to evaluate efficacy and potential of GLP-1 analogues to support market growth 181
11.3.4 FRANCE 184
11.3.4.1 Growing awareness to propel market growth 184
11.3.5 ITALY 186
11.3.5.1 Presence of major pharmaceutical and biotechnology companies to drive market 186
11.3.6 SPAIN 189
11.3.6.1 Favorable initiatives for research to drive market 189
11.3.7 NETHERLANDS 191
11.3.7.1 Growing awareness and strong focus on pharmaceutical R&D to support market growth 191
11.3.8 REST OF EUROPE 194
11.4 ASIA PACIFIC 196
11.4.1 ASIA PACIFIC: RECESSION IMPACT 196
11.4.2 CHINA 200
11.4.2.1 Expansion of major biotechnology and pharmaceutical companies in China to drive market 200
11.4.3 JAPAN 202
11.4.3.1 Growing availability of prominent GLP-1 drugs to drive market 202
11.4.4 INDIA 205
11.4.4.1 Strong initiatives to develop cost-effective and patient-friendly medications to aid market growth 205
11.4.5 AUSTRALIA 208
11.4.5.1 Access to GLP-1 drugs and government support to drive market 208
11.4.6 SOUTH KOREA 211
11.4.6.1 Collaborations in obesity drugs to propel market growth 211
11.4.7 REST OF ASIA PACIFIC 214
11.5 LATIN AMERICA 217
11.5.1 LATIN AMERICA: RECESSION IMPACT 217
11.5.2 BRAZIL 221
11.5.2.1 Brazil to hold largest market share in Latin America 221
11.5.3 MEXICO 223
11.5.3.1 Growing diabetes and obesity cases to support market growth 223
11.5.4 REST OF LATIN AMERICA 226
11.6 MIDDLE EAST 228
11.6.1 MIDDLE EAST: RECESSION IMPACT 229
11.6.2 GCC COUNTRIES 232
11.6.2.1 Saudi Arabia 234
11.6.2.1.1 Growing availability of GLP-1 drugs to support market growth 234
11.6.2.2 UAE 237
11.6.2.2.1 Growing regulatory approvals for GLP-1 drugs to support market growth 237
11.6.2.3 Rest of GCC countries 240
11.6.3 REST OF MIDDLE EAST 243
11.7 AFRICA 245
11.7.1 GROWING HEALTHCARE AND LIFE SCIENCE INDUSTRY TO SUPPORT GROWTH 245
11.7.2 AFRICA: RECESSION IMPACT 245
12 COMPETITIVE LANDSCAPE 249
12.1 OVERVIEW 249
12.2 KEY PLAYER STRATEGY/RIGHT TO WIN 249
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN GLP-1 ANALOGUES MARKET 249
12.3 REVENUE ANALYSIS 250
12.4 MARKET SHARE ANALYSIS 251
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 253
12.5.1 STARS 253
12.5.2 EMERGING LEADERS 253
12.5.3 PERVASIVE PLAYERS 253
12.5.4 PARTICIPANTS 253
12.6 COMPANY EVALUATION MATRIX: PLAYERS WITH PRODUCTS IN PIPELINE, 2023 255
12.6.1 STARS 255
12.6.2 EMERGING LEADERS 255
12.6.3 PERVASIVE PLAYERS 255
12.6.4 PARTICIPANTS 255
12.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 257
12.6.5.1 Company Footprint 257
12.6.5.2 Format footprint 259
12.6.5.3 Route of administration footprint 259
12.6.5.4 Indication footprint 260
12.6.5.5 Region footprint 262
12.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 262
12.7.1 PROGRESSIVE COMPANIES 262
12.7.2 RESPONSIVE COMPANIES 262
12.7.3 DYNAMIC COMPANIES 262
12.7.4 STARTING BLOCKS 263
12.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 264
12.8 VALUATION & FINANCIAL METRICS 266
12.8.1 FINANCIAL METRICS 266
12.8.2 COMPANY VALUATION 266
12.9 BRAND/PRODUCT COMPARISON 267
12.10 COMPETITIVE SCENARIO 269
12.10.1 PRODUCT APPROVALS 269
12.10.2 DEALS 270
12.10.3 EXPANSIONS 270
12.10.4 OTHER DEVELOPMENTS 271
13 COMPANY PROFILES 272
13.1 INTRODUCTION 272
13.2 KEY PLAYERS 272
13.2.1 NOVO NORDISK A/S 272
13.2.1.1 Business overview 272
13.2.1.2 Products offered 274
13.2.1.3 Recent developments 275
13.2.1.3.1 Product approvals 275
13.2.1.3.2 Expansions 275
13.2.1.3.3 Other developments 276
13.2.1.4 MnM view 276
13.2.1.4.1 Right to win 276
13.2.1.4.2 Strategic choices 276
13.2.1.4.3 Weaknesses & competitive threats 276
13.2.2 ELI LILLY AND COMPANY 277
13.2.2.1 Business overview 277
13.2.2.2 Products offered 279
13.2.2.3 Recent developments 279
13.2.2.3.1 Product approvals 279
13.2.2.3.2 Deals 280
13.2.2.3.3 Expansions 280
13.2.2.4 MnM view 281
13.2.2.4.1 Right to win 281
13.2.2.4.2 Strategic choices 281
13.2.2.4.3 Weaknesses & competitive threats 281
13.2.3 SANOFI 282
13.2.3.1 Business overview 282
13.2.3.2 Products offered 283
13.2.3.3 MnM view 284
13.2.3.3.1 Key strengths 284
13.2.3.3.2 Strategic choices 284
13.2.3.3.3 Weaknesses & competitive threats 284
13.2.4 ASTRAZENECA 285
13.2.4.1 Business overview 285
13.2.4.2 Products offered 286
13.2.4.3 Recent developments 287
13.2.4.3.1 Product approvals 287
13.2.4.4 MnM view 287
13.2.4.4.1 Right to win 287
13.2.4.4.2 Strategic choices 287
13.2.4.4.3 Weaknesses & competitive threats 287
13.2.5 JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. 288
13.2.5.1 Business overview 288
13.2.5.2 Products offered 289
13.2.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 290
13.2.6.1 Business overview 290
13.2.6.2 Products in pipeline 291
13.2.6.3 Recent developments 292
13.2.6.3.1 Deals 292
13.2.6.3.2 Other developments 292
13.2.7 INNOVENT 293
13.2.7.1 Business overview 293
13.2.7.2 Products in pipeline 294
13.2.7.3 Recent developments 294
13.2.7.3.1 Other developments 294
13.2.8 PAIGE BIOPHARMACEUTICAL (SUZHOU) CO., LTD. 295
13.2.8.1 Business overview 295
13.2.8.2 Products in pipeline 295
13.2.9 SCIWIND BIOSCIENCES CO., LTD. 296
13.2.9.1 Business overview 296
13.2.9.2 Products in pipeline 296
13.2.9.3 Recent developments 297
13.2.9.3.1 Deals 297
13.2.9.3.2 Other developments 297
13.2.10 ZEALAND PHARMA A/S 298
13.2.10.1 Business overview 298
13.2.10.2 Products in pipeline 299
13.2.10.3 Recent developments 299
13.2.10.3.1 Deals 299
13.2.10.3.2 Other developments 299
13.2.11 BEIJING DONGFANG BAITAI BIOTECHNOLOGY CO., LTD (EASTERN BIOTECH) 300
13.2.11.1 Business overview 300
13.2.11.2 Products in pipeline 300
13.3 OTHER PLAYERS 301
13.3.1 SUN PHARMACEUTICAL INDUSTRIES LTD. 301
13.3.2 VTV THERAPEUTICS 301
13.3.3 TERNS PHARMACEUTICALS, INC. 302
13.3.4 ALTIMMUNE 302
13.3.5 SCOHIA PHARMA, INC. 303
13.3.6 STRUCTURE THERAPEUTICS 303
13.3.7 NEUROBO PHARMACEUTICALS, INC. 304
13.3.8 I2O THERAPEUTICS, INC. 304
13.3.9 AMGEN INC. 305
13.3.10 PFIZER INC. 305
13.3.11 MERCK & CO., INC. 306
13.3.12 HANMI PHARM CO., LTD. 306
13.3.13 VIKING THERAPEUTICS 307
13.3.14 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. 307
14 APPENDIX 308
14.1 DISCUSSION GUIDE 308
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 312
14.3 CUSTOMIZATION OPTIONS 314
14.4 RELATED REPORTS 314
14.5 AUTHOR DETAILS 315
LIST OF TABLES
TABLE 1 US HEALTH EXPENDITURE, 2023–2030 (USD MILLION) 43
TABLE 2 GLP-1 ANALOGUES MARKET: IMPACT ANALYSIS 54
TABLE 3 AVERAGE SELLING PRICE RANGE OF TOP GLP-1 ANALOGUES (2023–2024) 61
TABLE 4 GLP-1 ANALOGUES IN CLINICAL PIPELINE (AS OF MAY 2024) 66
TABLE 5 TOP 20 PATENT OWNERS IN GLP-1 ANALOGUES MARKET, 2014–2024 75
TABLE 6 INDICATIVE LIST OF PATENTS IN GLP-1 ANALOGUES MARKET, 2022–2024 76
TABLE 7 GLP-1 ANALOGUES MARKET: ROLE OF RAW MATERIAL VENDORS 79
TABLE 8 GLP-1 ANALOGUES MARKET: ROLE OF PRODUCT PROVIDERS AND
PHASE 3 PIPELINE PRODUCT COMPANIES 80
TABLE 9 GLP-1 ANALOGUES MARKET: ROLE OF END USERS 80
TABLE 10 GLP-1 ANALOGUES MARKET: ROLE OF REGULATORY AUTHORITIES 81
TABLE 11 GLP-1 ANALOGUES MARKET: PORTER’S FIVE FORCES ANALYSIS 81
TABLE 12 BUYING CRITERIA FOR GLP-1 ANALOGUES, BY END USER 84
TABLE 13 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 86
TABLE 14 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 86
TABLE 15 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 87
TABLE 16 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
TABLE 17 GLP-1 ANALOGUES MARKET: DETAILED LIST OF CONFERENCES &
EVENTS, 2024–2025 88
TABLE 18 GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION) 92
TABLE 19 GLP-1 ANALOGUES MARKET FOR ANTI-OBESITY PRODUCTS (MILLION UNITS) 92
TABLE 20 OZEMPIC MARKET, BY REGION, 2022–2032 (USD BILLION) 93
TABLE 21 NORTH AMERICA: OZEMPIC MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 93
TABLE 22 EUROPE: OZEMPIC MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 94
TABLE 23 ASIA PACIFIC: OZEMPIC MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 94
TABLE 24 LATIN AMERICA: OZEMPIC MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 94
TABLE 25 MIDDLE EAST: OZEMPIC MARKET, BY REGION, 2022–2032 (USD BILLION) 95
TABLE 26 GCC COUNTRIES: OZEMPIC MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 95
TABLE 27 TRULICITY MARKET, BY REGION, 2022–2032 (USD BILLION) 96
TABLE 28 NORTH AMERICA: TRULICITY MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 96
TABLE 29 EUROPE: TRULICITY MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 96
TABLE 30 ASIA PACIFIC: TRULICITY MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 97
TABLE 31 LATIN AMERICA: TRULICITY MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 97
TABLE 32 MIDDLE EAST: TRULICITY MARKET, BY REGION, 2022–2032 (USD BILLION) 97
TABLE 33 GCC COUNTRIES: TRULICITY MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 98
TABLE 34 MOUNJARO MARKET, BY REGION, 2022–2032 (USD BILLION) 98
TABLE 35 NORTH AMERICA: MOUNJARO MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 99
TABLE 36 EUROPE: MOUNJARO MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 99
TABLE 37 ASIA PACIFIC: MOUNJARO MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 99
TABLE 38 LATIN AMERICA: MOUNJARO MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 100
TABLE 39 MIDDLE EAST: MOUNJARO MARKET, BY REGION, 2022–2032 (USD BILLION) 100
TABLE 40 GCC COUNTRIES: MOUNJARO MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 100
TABLE 41 WEGOVY MARKET, BY REGION, 2022–2032 (USD BILLION) 101
TABLE 42 NORTH AMERICA: WEGOVY MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 101
TABLE 43 EUROPE: WEGOVY MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 102
TABLE 44 ASIA PACIFIC: WEGOVY MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 102
TABLE 45 LATIN AMERICA: WEGOVY MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 103
TABLE 46 MIDDLE EAST: WEGOVY MARKET, BY REGION, 2022–2032 (USD BILLION) 103
TABLE 47 GCC COUNTRIES: WEGOVY MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 103
TABLE 48 RYBELSUS MARKET, BY REGION, 2022–2032 (USD BILLION) 104
TABLE 49 NORTH AMERICA: RYBELSUS MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 104
TABLE 50 EUROPE: RYBELSUS MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 105
TABLE 51 ASIA PACIFIC: RYBELSUS MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 105
TABLE 52 LATIN AMERICA: RYBELSUS MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 105
TABLE 53 MIDDLE EAST: RYBELSUS MARKET, BY REGION, 2022–2032 (USD BILLION) 106
TABLE 54 GCC COUNTRIES: RYBELSUS MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 106
TABLE 55 SAXENDA MARKET, BY REGION, 2022–2032 (USD BILLION) 107
TABLE 56 NORTH AMERICA: SAXENDA MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 107
TABLE 57 EUROPE: SAXENDA MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 107
TABLE 58 ASIA PACIFIC: SAXENDA MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 108
TABLE 59 LATIN AMERICA: SAXENDA MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 108
TABLE 60 MIDDLE EAST: SAXENDA MARKET, BY REGION, 2022–2032 (USD BILLION) 108
TABLE 61 GCC COUNTRIES: SAXENDA MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 109
TABLE 62 VICTOZA MARKET, BY REGION, 2022–2032 (USD BILLION) 109
TABLE 63 NORTH AMERICA: VICTOZA MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 110
TABLE 64 EUROPE: VICTOZA MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 110
TABLE 65 ASIA PACIFIC: VICTOZA MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 110
TABLE 66 LATIN AMERICA: VICTOZA MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 111
TABLE 67 MIDDLE EAST: VICTOZA MARKET, BY REGION, 2022–2032 (USD BILLION) 111
TABLE 68 GCC COUNTRIES: VICTOZA MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 111
TABLE 69 XULTOPHY MARKET, BY REGION, 2022–2032 (USD BILLION) 112
TABLE 70 SOLIQUA MARKET, BY REGION, 2022–2032 (USD BILLION) 112
TABLE 71 ZEPBOUND MARKET, BY REGION, 2022–2032 (USD BILLION) 113
TABLE 72 NORTH AMERICA: ZEPBOUND MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 113
TABLE 73 EUROPE: ZEPBOUND MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 114
TABLE 74 ASIA PACIFIC: ZEPBOUND MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 114
TABLE 75 LATIN AMERICA: ZEPBOUND MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 115
TABLE 76 MIDDLE EAST: ZEPBOUND MARKET, BY REGION, 2022–2032 (USD BILLION) 115
TABLE 77 GCC COUNTRIES: ZEPBOUND MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 115
TABLE 78 BYDUREON MARKET, BY REGION, 2022–2032 (USD BILLION) 116
TABLE 79 OTHER PRODUCTS MARKET, BY REGION, 2022–2032 (USD BILLION) 117
TABLE 80 GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION) 119
TABLE 81 SINGLE-DOSE GLP-1 ANALOGUES MARKET, BY REGION,
2022–2032 (USD BILLION) 120
TABLE 82 NORTH AMERICA: SINGLE-DOSE GLP-1 ANALOGUES MARKET,
BY COUNTRY, 2022–2032 (USD BILLION) 120
TABLE 83 EUROPE: SINGLE-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY,
2022–2032 (USD BILLION) 120
TABLE 84 ASIA PACIFIC: SINGLE-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY,
2022–2032 (USD BILLION) 121
TABLE 85 LATIN AMERICA: SINGLE-DOSE GLP-1 ANALOGUES MARKET,
BY COUNTRY, 2022–2032 (USD BILLION) 121
TABLE 86 MIDDLE EAST: SINGLE-DOSE GLP-1 ANALOGUES MARKET,
BY COUNTRY, 2022–2032 (USD BILLION) 121
TABLE 87 GCC COUNTRIES: SINGLE-DOSE GLP-1 ANALOGUES MARKET,
BY COUNTRY, 2022–2032 (USD BILLION) 122
TABLE 88 MULTI-DOSE GLP-1 ANALOGUES MARKET, BY REGION, 2022–2032 (USD BILLION) 123
TABLE 89 NORTH AMERICA: MULTI-DOSE GLP-1 ANALOGUES MARKET,
BY COUNTRY, 2022–2032 (USD BILLION) 123
TABLE 90 EUROPE: MULTI-DOSE GLP-1 ANALOGUES MARKET, BY COUNTRY,
2022–2032 (USD BILLION) 123
TABLE 91 ASIA PACIFIC: MULTI-DOSE GLP-1 ANALOGUES MARKET,
BY COUNTRY, 2022–2032 (USD BILLION) 124
TABLE 92 LATIN AMERICA: MULTI-DOSE GLP-1 ANALOGUES MARKET,
BY COUNTRY, 2022–2032 (USD BILLION) 124
TABLE 93 MIDDLE EAST: MULTI-DOSE GLP-1 ANALOGUES MARKET,
BY COUNTRY, 2022–2032 (USD BILLION) 124
TABLE 94 GCC COUNTRIES: MULTI-DOSE GLP-1 ANALOGUES MARKET,
BY COUNTRY, 2022–2032 (USD BILLION) 125
TABLE 95 GLP-1 ANALOGUE TABLETS MARKET, BY REGION, 2022–2032 (USD BILLION) 125
TABLE 96 NORTH AMERICA: GLP-1 ANALOGUE TABLETS MARKET,
BY COUNTRY, 2022–2032 (USD BILLION) 126
TABLE 97 EUROPE: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY,
2022–2032 (USD BILLION) 126
TABLE 98 ASIA PACIFIC: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY,
2022–2032 (USD BILLION) 126
TABLE 99 LATIN AMERICA: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY,
2022–2032 (USD BILLION) 127
TABLE 100 MIDDLE EAST: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY,
2022–2032 (USD BILLION) 127
TABLE 101 GCC COUNTRIES: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY,
2022–2032 (USD BILLION) 127
TABLE 102 GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD BILLION) 129
TABLE 103 SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET,
BY TYPE, 2022–2032 (USD BILLION) 130
TABLE 104 SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET,
BY REGION, 2022–2032 (USD BILLION) 130
TABLE 105 NORTH AMERICA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 130
TABLE 106 EUROPE: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET,
BY COUNTRY, 2022–2032 (USD BILLION) 131
TABLE 107 ASIA PACIFIC: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET,
BY COUNTRY, 2022–2032 (USD BILLION) 131
TABLE 108 LATIN AMERICA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 132
TABLE 109 MIDDLE EAST: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET,
BY REGION, 2022–2032 (USD BILLION) 132
TABLE 110 GCC COUNTRIES: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 132
TABLE 111 GLP-1 ANALOGUE PEN INJECTORS MARKET, BY REGION,
2022–2032 (USD BILLION) 133
TABLE 112 NORTH AMERICA: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 133
TABLE 113 EUROPE: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY COUNTRY,
2022–2032 (USD BILLION) 134
TABLE 114 ASIA PACIFIC: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY COUNTRY,
2022–2032 (USD BILLION) 134
TABLE 115 LATIN AMERICA: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY COUNTRY,
2022–2032 (USD BILLION) 135
TABLE 116 MIDDLE EAST: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY REGION,
2022–2032 (USD BILLION) 135
TABLE 117 GCC COUNTRIES: GLP-1 ANALOGUE PEN INJECTORS MARKET,
BY COUNTRY, 2022–2032 (USD BILLION) 135
TABLE 118 GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY REGION,
2022–2032 (USD BILLION) 136
TABLE 119 NORTH AMERICA: GLP-1 ANALOGUE AUTOINJECTORS MARKET,
BY COUNTRY, 2022–2032 (USD BILLION) 137
TABLE 120 EUROPE: GLP-1 ANALOGUE AUTOINJECTORS MARKET,
BY COUNTRY, 2022–2032 (USD BILLION) 137
TABLE 121 ASIA PACIFIC: GLP-1 ANALOGUE AUTOINJECTORS MARKET,
BY COUNTRY, 2022–2032 (USD BILLION) 137
TABLE 122 LATIN AMERICA: GLP-1 ANALOGUE AUTOINJECTORS MARKET,
BY COUNTRY, 2022–2032 (USD BILLION) 138
TABLE 123 MIDDLE EAST: GLP-1 ANALOGUE AUTOINJECTORS MARKET,
BY REGION, 2022–2032 (USD BILLION) 138
TABLE 124 GCC COUNTRIES: GLP-1 ANALOGUE AUTOINJECTORS MARKET,
BY COUNTRY, 2022–2032 (USD BILLION) 138
TABLE 125 ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET,
BY REGION, 2022–2032 (USD BILLION) 139
TABLE 126 NORTH AMERICA: ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET,
BY COUNTRY, 2022–2032 (USD BILLION) 140
TABLE 127 EUROPE: ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET,
BY COUNTRY, 2022–2032 (USD BILLION) 140
TABLE 128 ASIA PACIFIC: ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET,
BY COUNTRY, 2022–2032 (USD BILLION) 140
TABLE 129 LATIN AMERICA: ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET,
BY COUNTRY, 2022–2032 (USD BILLION) 141
TABLE 130 MIDDLE EAST: ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET,
BY REGION, 2022–2032 (USD MILLION) 141
TABLE 131 GCC COUNTRIES: ORALLY ADMINISTERED GLP-1 ANALOGUES MARKET,
BY COUNTRY, 2022–2032 (USD BILLION) 141
TABLE 132 GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION) 143
TABLE 133 GLP-1 ANALOGUES MARKET FOR DIABETES, BY REGION,
2022–2032 (USD BILLION) 144
TABLE 134 NORTH AMERICA: GLP-1 ANALOGUES MARKET FOR DIABETES,
BY COUNTRY, 2022–2032 (USD BILLION) 144
TABLE 135 EUROPE: GLP-1 ANALOGUES MARKET FOR DIABETES, BY COUNTRY,
2022–2032 (USD BILLION) 144
TABLE 136 ASIA PACIFIC: GLP-1 ANALOGUES MARKET FOR DIABETES,
BY COUNTRY, 2022–2032 (USD BILLION) 145
TABLE 137 LATIN AMERICA: GLP-1 ANALOGUES MARKET FOR DIABETES,
BY COUNTRY, 2022–2032 (USD BILLION) 145
TABLE 138 MIDDLE EAST: GLP-1 ANALOGUES MARKET FOR DIABETES,
BY REGION, 2022–2032 (USD BILLION) 145
TABLE 139 GCC COUNTRIES: GLP-1 ANALOGUES MARKET FOR DIABETES,
BY COUNTRY, 2022–2032 (USD BILLION) 146
TABLE 140 GLP-1 ANALOGUES MARKET FOR OBESITY, BY REGION, 2022–2032 (USD BILLION) 147
TABLE 141 NORTH AMERICA: GLP-1 ANALOGUES MARKET FOR OBESITY,
BY COUNTRY, 2022–2032 (USD BILLION) 147
TABLE 142 EUROPE: GLP-1 ANALOGUES MARKET FOR OBESITY,
BY COUNTRY, 2022–2032 (USD BILLION) 147
TABLE 143 ASIA PACIFIC: GLP-1 ANALOGUES MARKET FOR OBESITY,
BY COUNTRY, 2022–2032 (USD BILLION) 148
TABLE 144 LATIN AMERICA: GLP-1 ANALOGUES MARKET FOR OBESITY,
BY COUNTRY, 2022–2032 (USD BILLION) 148
TABLE 145 MIDDLE EAST: GLP-1 ANALOGUES MARKET FOR OBESITY,
BY REGION, 2022–2032 (USD BILLION) 148
TABLE 146 GCC COUNTRIES: GLP-1 ANALOGUES MARKET FOR OBESITY,
BY COUNTRY, 2022–2032 (USD BILLION) 149
TABLE 147 GLP-1 ANALOGUES MARKET FOR OTHER INDICATIONS,
BY REGION, 2022–2032 (USD BILLION) 150
TABLE 148 NORTH AMERICA: GLP-1 ANALOGUES MARKET FOR OTHER INDICATIONS,
BY COUNTRY, 2022–2032 (USD BILLION) 150
TABLE 149 EUROPE: GLP-1 ANALOGUES MARKET FOR OTHER INDICATIONS,
BY COUNTRY, 2022–2032 (USD BILLION) 150
TABLE 150 ASIA PACIFIC: GLP-1 ANALOGUES MARKET FOR OTHER INDICATIONS,
BY COUNTRY, 2022–2032 (USD BILLION) 151
TABLE 151 LATIN AMERICA: GLP-1 ANALOGUES MARKET FOR OTHER INDICATIONS,
BY COUNTRY, 2022–2032 (USD BILLION) 151
TABLE 152 MIDDLE EAST: GLP-1 ANALOGUES MARKET FOR OTHER INDICATIONS,
BY REGION, 2022–2032 (USD BILLION) 151
TABLE 153 GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION) 153
TABLE 154 GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS,
BY REGION, 2022–2032 (USD BILLION) 154
TABLE 155 NORTH AMERICA: GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2022–2032 (USD BILLION) 154
TABLE 156 EUROPE: GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2022–2032 (USD BILLION) 154
TABLE 157 ASIA PACIFIC: GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2022–2032 (USD BILLION) 155
TABLE 158 LATIN AMERICA: GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2022–2032 (USD BILLION) 155
TABLE 159 MIDDLE EAST: GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS,
BY REGION, 2022–2032 (USD BILLION) 155
TABLE 160 GCC COUNTRIES: GLP-1 ANALOGUES MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2022–2032 (USD BILLION) 156
TABLE 161 GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES,
BY REGION, 2022–2032 (USD BILLION) 157
TABLE 162 NORTH AMERICA: GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2032 (USD BILLION) 157
TABLE 163 EUROPE: GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES,
BY COUNTRY, 2022–2032 (USD BILLION) 157
TABLE 164 ASIA PACIFIC: GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES,
BY COUNTRY, 2022–2032 (USD BILLION) 158
TABLE 165 LATIN AMERICA: GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2032 (USD BILLION) 158
TABLE 166 MIDDLE EAST: GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES,
BY REGION, 2022–2032 (USD BILLION) 158
TABLE 167 GCC COUNTRIES: GLP-1 ANALOGUES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2032 (USD BILLION) 159
TABLE 168 GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS,
BY REGION, 2022–2032 (USD BILLION) 160
TABLE 169 NORTH AMERICA: GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2032 (USD BILLION) 160
TABLE 170 EUROPE: GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS,
BY COUNTRY, 2022–2032 (USD BILLION) 160
TABLE 171 ASIA PACIFIC: GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2032 (USD BILLION) 161
TABLE 172 LATIN AMERICA: GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2032 (USD BILLION) 161
TABLE 173 MIDDLE EAST: GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2022–2032 (USD BILLION) 161
TABLE 174 GCC COUNTRIES: GLP-1 ANALOGUES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2032 (USD BILLION) 162
TABLE 175 GLP-1 ANALOGUES MARKET, BY REGION, 2022–2032 (USD BILLION) 164
TABLE 176 NORTH AMERICA: GLP-1 ANALOGUES MARKET, BY PRODUCT,
2022–2032 (USD BILLION) 166
TABLE 177 NORTH AMERICA: GLP-1 ANALOGUES MARKET, BY FORMAT,
2022–2032 (USD BILLION) 166
TABLE 178 NORTH AMERICA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION) 167
TABLE 179 NORTH AMERICA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION) 167
TABLE 180 NORTH AMERICA: GLP-1 ANALOGUES MARKET, BY INDICATION,
2022–2032 (USD BILLION) 167
TABLE 181 NORTH AMERICA: GLP-1 ANALOGUES MARKET, BY END USER,
2022–2032 (USD BILLION) 168
TABLE 182 NORTH AMERICA: GLP-1 ANALOGUES MARKET, BY COUNTRY,
2022–2032 (USD BILLION) 168
TABLE 183 US: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION) 169
TABLE 184 US: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION) 170
TABLE 185 US: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD BILLION) 170
TABLE 186 US: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET,
BY TYPE, 2022–2032 (USD BILLION) 170
TABLE 187 US: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION) 171
TABLE 188 US: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION) 171
TABLE 189 CANADA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION) 172
TABLE 190 CANADA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION) 172
TABLE 191 CANADA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD BILLION) 173
TABLE 192 CANADA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET,
BY TYPE, 2022–2032 (USD BILLION) 173
TABLE 193 CANADA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION) 173
TABLE 194 CANADA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION) 174
TABLE 195 EUROPE: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION) 176
TABLE 196 EUROPE: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION) 176
TABLE 197 EUROPE: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD BILLION) 177
TABLE 198 EUROPE: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET,
BY TYPE, 2022–2032 (USD BILLION) 177
TABLE 199 EUROPE: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION) 177
TABLE 200 EUROPE: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION) 178
TABLE 201 EUROPE: GLP-1 ANALOGUES MARKET, BY COUNTRY, 2022–2032 (USD BILLION) 178
TABLE 202 GERMANY: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION) 179
TABLE 203 GERMANY: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION) 180
TABLE 204 GERMANY: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD BILLION) 180
TABLE 205 GERMANY: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET,
BY TYPE, 2022–2032 (USD BILLION) 180
TABLE 206 GERMANY: GLP-1 ANALOGUES MARKET, BY INDICATION,
2022–2032 (USD BILLION) 181
TABLE 207 GERMANY: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION) 181
TABLE 208 UK: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION) 182
TABLE 209 UK: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION) 182
TABLE 210 UK: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD BILLION) 182
TABLE 211 UK: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET,
BY TYPE, 2022–2032 (USD BILLION) 183
TABLE 212 UK: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION) 183
TABLE 213 UK: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION) 183
TABLE 214 FRANCE: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION) 184
TABLE 215 FRANCE: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION) 185
TABLE 216 FRANCE: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD BILLION) 185
TABLE 217 FRANCE: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET,
BY TYPE, 2022–2032 (USD BILLION) 185
TABLE 218 FRANCE: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION) 186
TABLE 219 FRANCE: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION) 186
TABLE 220 ITALY: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION) 187
TABLE 221 ITALY: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION) 187
TABLE 222 ITALY: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD BILLION) 187
TABLE 223 ITALY: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET,
BY TYPE, 2022–2032 (USD BILLION) 188
TABLE 224 ITALY: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION) 188
TABLE 225 ITALY: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION) 188
TABLE 226 SPAIN: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION) 189
TABLE 227 SPAIN: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION) 190
TABLE 228 SPAIN: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD BILLION) 190
TABLE 229 SPAIN: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET,
BY TYPE, 2022–2032 (USD BILLION) 190
TABLE 230 SPAIN: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION) 191
TABLE 231 SPAIN: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION) 191
TABLE 232 NETHERLANDS: GLP-1 ANALOGUES MARKET, BY PRODUCT,
2022–2032 (USD BILLION) 192
TABLE 233 NETHERLANDS: GLP-1 ANALOGUES MARKET, BY FORMAT,
2022–2032 (USD BILLION) 192
TABLE 234 NETHERLANDS: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION) 193
TABLE 235 NETHERLANDS: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION) 193
TABLE 236 NETHERLANDS: GLP-1 ANALOGUES MARKET, BY INDICATION,
2022–2032 (USD BILLION) 193
TABLE 237 NETHERLANDS: GLP-1 ANALOGUES MARKET, BY END USER,
2022–2032 (USD BILLION) 194
TABLE 238 REST OF EUROPE: GLP-1 ANALOGUES MARKET, BY PRODUCT,
2022–2032 (USD BILLION) 194
TABLE 239 REST OF EUROPE: GLP-1 ANALOGUES MARKET, BY FORMAT,
2022–2032 (USD BILLION) 195
TABLE 240 REST OF EUROPE: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION) 195
TABLE 241 REST OF EUROPE: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION) 195
TABLE 242 REST OF EUROPE: GLP-1 ANALOGUES MARKET, BY INDICATION,
2022–2032 (USD BILLION) 196
TABLE 243 REST OF EUROPE: GLP-1 ANALOGUES MARKET, BY END USER,
2022–2032 (USD BILLION) 196
TABLE 244 ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY PRODUCT,
2022–2032 (USD BILLION) 197
TABLE 245 ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY FORMAT,
2022–2032 (USD BILLION) 198
TABLE 246 ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD BILLION) 198
TABLE 247 ASIA PACIFIC: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET,
BY TYPE, 2022–2032 (USD BILLION) 198
TABLE 248 ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY INDICATION,
2022–2032 (USD BILLION) 199
TABLE 249 ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY END USER,
2022–2032 (USD BILLION) 199
TABLE 250 ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY COUNTRY,
2022–2032 (USD BILLION) 199
TABLE 251 CHINA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION) 200
TABLE 252 CHINA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION) 201
TABLE 253 CHINA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD BILLION) 201
TABLE 254 CHINA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET,
BY TYPE, 2022–2032 (USD BILLION) 201
TABLE 255 CHINA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION) 202
TABLE 256 CHINA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION) 202
TABLE 257 JAPAN: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION) 203
TABLE 258 JAPAN: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION) 203
TABLE 259 JAPAN: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD BILLION) 204
TABLE 260 JAPAN: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET,
BY TYPE, 2022–2032 (USD BILLION) 204
TABLE 261 JAPAN: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION) 204
TABLE 262 JAPAN: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION) 205
TABLE 263 INDIA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION) 206
TABLE 264 INDIA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION) 206
TABLE 265 INDIA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD BILLION) 207
TABLE 266 INDIA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET,
BY TYPE, 2022–2032 (USD BILLION) 207
TABLE 267 INDIA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION) 207
TABLE 268 INDIA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION) 208
TABLE 269 AUSTRALIA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION) 209
TABLE 270 AUSTRALIA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION) 209
TABLE 271 AUSTRALIA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD BILLION) 210
TABLE 272 AUSTRALIA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET,
BY TYPE, 2022–2032 (USD BILLION) 210
TABLE 273 AUSTRALIA: GLP-1 ANALOGUES MARKET, BY INDICATION,
2022–2032 (USD BILLION) 210
TABLE 274 AUSTRALIA: GLP-1 ANALOGUES MARKET, BY END USER,
2022–2032 (USD BILLION) 211
TABLE 275 SOUTH KOREA: GLP-1 ANALOGUES MARKET, BY PRODUCT,
2022–2032 (USD BILLION) 212
TABLE 276 SOUTH KOREA: GLP-1 ANALOGUES MARKET, BY FORMAT,
2022–2032 (USD BILLION) 212
TABLE 277 SOUTH KOREA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION) 213
TABLE 278 SOUTH KOREA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION) 213
TABLE 279 SOUTH KOREA: GLP-1 ANALOGUES MARKET, BY INDICATION,
2022–2032 (USD BILLION) 213
TABLE 280 SOUTH KOREA: GLP-1 ANALOGUES MARKET, BY END USER,
2022–2032 (USD BILLION) 214
TABLE 281 REST OF ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY PRODUCT,
2022–2032 (USD BILLION) 215
TABLE 282 REST OF ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY FORMAT,
2022–2032 (USD BILLION) 215
TABLE 283 REST OF ASIA PACIFIC: GLP-1 ANALOGUES MARKET,
BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION) 216
TABLE 284 REST OF ASIA PACIFIC: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION) 216
TABLE 285 REST OF ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY INDICATION,
2022–2032 (USD BILLION) 216
TABLE 286 REST OF ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY END USER,
2022–2032 (USD BILLION) 217
TABLE 287 LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY PRODUCT,
2022–2032 (USD BILLION) 218
TABLE 288 LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY FORMAT,
2022–2032 (USD BILLION) 218
TABLE 289 LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION) 219
TABLE 290 LATIN AMERICA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION) 219
TABLE 291 LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY INDICATION,
2022–2032 (USD BILLION) 219
TABLE 292 LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY END USER,
2022–2032 (USD BILLION) 220
TABLE 293 LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY COUNTRY,
2022–2032 (USD BILLION) 220
TABLE 294 BRAZIL: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION) 221
TABLE 295 BRAZIL: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION) 222
TABLE 296 BRAZIL: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD BILLION) 222
TABLE 297 BRAZIL: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET,
BY TYPE, 2022–2032 (USD BILLION) 222
TABLE 298 BRAZIL: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION) 223
TABLE 299 BRAZIL: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION) 223
TABLE 300 MEXICO: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION) 224
TABLE 301 MEXICO: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION) 224
TABLE 302 MEXICO: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD BILLION) 225
TABLE 303 MEXICO: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET,
BY TYPE, 2022–2032 (USD BILLION) 225
TABLE 304 MEXICO: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION) 225
TABLE 305 MEXICO: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION) 226
TABLE 306 REST OF LATIN AMERICA: GLP-1 ANALOGUES MARKET,
BY PRODUCT, 2022–2032 (USD BILLION) 226
TABLE 307 REST OF LATIN AMERICA: GLP-1 ANALOGUES MARKET,
BY FORMAT, 2022–2032 (USD BILLION) 227
TABLE 308 REST OF LATIN AMERICA: GLP-1 ANALOGUES MARKET,
BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION) 227
TABLE 309 REST OF LATIN AMERICA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION) 227
TABLE 310 REST OF LATIN AMERICA: GLP-1 ANALOGUES MARKET,
BY INDICATION, 2022–2032 (USD BILLION) 228
TABLE 311 REST OF LATIN AMERICA: GLP-1 ANALOGUES MARKET,
BY END USER, 2022–2032 (USD BILLION) 228
TABLE 312 MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY PRODUCT,
2022–2032 (USD BILLION) 229
TABLE 313 MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY FORMAT,
2022–2032 (USD BILLION) 230
TABLE 314 MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION) 230
TABLE 315 MIDDLE EAST: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET,
BY TYPE, 2022–2032 (USD BILLION) 230
TABLE 316 MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY INDICATION,
2022–2032 (USD BILLION) 231
TABLE 317 MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY END USER,
2022–2032 (USD BILLION) 231
TABLE 318 MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY REGION,
2022–2032 (USD BILLION) 231
TABLE 319 GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY PRODUCT,
2022–2032 (USD BILLION) 232
TABLE 320 GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY FORMAT,
2022–2032 (USD BILLION) 232
TABLE 321 GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION) 233
TABLE 322 GCC COUNTRIES: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION) 233
TABLE 323 GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY INDICATION,
2022–2032 (USD BILLION) 233
TABLE 324 GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY END USER,
2022–2032 (USD BILLION) 234
TABLE 325 GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY COUNTRY,
2022–2032 (USD BILLION) 234
TABLE 326 SAUDI ARABIA: GLP-1 ANALOGUES MARKET, BY PRODUCT,
2022–2032 (USD BILLION) 235
TABLE 327 SAUDI ARABIA: GLP-1 ANALOGUES MARKET, BY FORMAT,
2022–2032 (USD BILLION) 235
TABLE 328 SAUDI ARABIA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION) 236
TABLE 329 SAUDI ARABIA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET,
BY TYPE, 2022–2032 (USD BILLION) 236
TABLE 330 SAUDI ARABIA: GLP-1 ANALOGUES MARKET, BY INDICATION,
2022–2032 (USD BILLION) 236
TABLE 331 SAUDI ARABIA: GLP-1 ANALOGUES MARKET, BY END USER,
2022–2032 (USD BILLION) 237
TABLE 332 UAE: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION) 238
TABLE 333 UAE: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION) 238
TABLE 334 UAE: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD BILLION) 239
TABLE 335 UAE: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET,
BY TYPE, 2022–2032 (USD BILLION) 239
TABLE 336 UAE: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION) 239
TABLE 337 UAE: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION) 240
TABLE 338 REST OF GCC COUNTRIES: GLP-1 ANALOGUES MARKET,
BY PRODUCT, 2022–2032 (USD BILLION) 240
TABLE 339 REST OF GCC COUNTRIES: GLP-1 ANALOGUES MARKET,
BY FORMAT, 2022–2032 (USD BILLION) 241
TABLE 340 REST OF GCC COUNTRIES: GLP-1 ANALOGUES MARKET,
BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION) 241
TABLE 341 REST OF GCC COUNTRIES: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION) 241
TABLE 342 REST OF GCC COUNTRIES: GLP-1 ANALOGUES MARKET,
BY INDICATION, 2022–2032 (USD BILLION) 242
TABLE 343 REST OF GCC COUNTRIES: GLP-1 ANALOGUES MARKET,
BY END USER, 2022–2032 (USD BILLION) 242
TABLE 344 REST OF MIDDLE EAST: GLP-1 ANALOGUES MARKET,
BY PRODUCT, 2022–2032 (USD BILLION) 243
TABLE 345 REST OF MIDDLE EAST: GLP-1 ANALOGUES MARKET,
BY FORMAT, 2022–2032 (USD BILLION) 243
TABLE 346 REST OF MIDDLE EAST: GLP-1 ANALOGUES MARKET,
BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION) 244
TABLE 347 REST OF MIDDLE EAST: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION) 244
TABLE 348 REST OF MIDDLE EAST: GLP-1 ANALOGUES MARKET,
BY INDICATION, 2022–2032 (USD BILLION) 244
TABLE 349 REST OF MIDDLE EAST: GLP-1 ANALOGUES MARKET,
BY END USER, 2022–2032 (USD BILLION) 245
TABLE 350 AFRICA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION) 246
TABLE 351 AFRICA: GLP-1 ANALOGUES MARKET, BY FORMAT, 2022–2032 (USD BILLION) 246
TABLE 352 AFRICA: GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD BILLION) 247
TABLE 353 AFRICA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET,
BY TYPE, 2022–2032 (USD BILLION) 247
TABLE 354 AFRICA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION) 247
TABLE 355 AFRICA: GLP-1 ANALOGUES MARKET, BY END USER, 2022–2032 (USD BILLION) 248
TABLE 356 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES 249
TABLE 357 GLP-1 ANALOGUES MARKET: DEGREE OF COMPETITION 252
TABLE 358 GLP-1 ANALOGUES MARKET: FORMAT FOOTPRINT 259
TABLE 359 GLP-1 ANALOGUES MARKET: ROUTE OF ADMINISTRATION FOOTPRINT 259
TABLE 360 GLP-1 ANALOGUES MARKET: ROUTE OF ADMINISTRATION FOOTPRINT
(PLAYERS WITH PRODUCTS IN PIPELINE) 259
TABLE 361 GLP-1 ANALOGUES MARKET: INDICATION FOOTPRINT (KEY PLAYERS) 260
TABLE 362 GLP-1 ANALOGUES MARKET: INDICATION FOOTPRINT
(PLAYERS WITH PRODUCTS IN PIPELINE) 261
TABLE 363 GLP-1 ANALOGUES MARKET: REGION FOOTPRINT (KEY PLAYERS) 262
TABLE 364 GLP-1 ANALOGUES MARKET: DETAILED LIST OF KEY START-UPS/SMES 264
TABLE 365 GLP-1 ANALOGUES MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS 265
TABLE 366 GLP-1 ANALOGUES MARKET: PRODUCT APPROVALS, JANUARY 2021–MAY 2024 269
TABLE 367 GLP-1 ANALOGUES MARKET: DEALS, JANUARY 2021–MAY 2024 270
TABLE 368 GLP-1 ANALOGUES MARKET: EXPANSIONS, JANUARY 2021–MAY 2024 270
TABLE 369 GLP-1 ANALOGUES MARKET: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024 271
TABLE 370 NOVO NORDISK A/S: COMPANY OVERVIEW 272
TABLE 371 NOVO NORDISK A/S: PRODUCTS OFFERED 274
TABLE 372 NOVO NORDISK A/S: PRODUCT APPROVALS, JANUARY 2021–APRIL 2024 275
TABLE 373 NOVO NORDISK A/S: EXPANSIONS, JANUARY 2021–APRIL 2024 275
TABLE 374 NOVO NORDISK A/S: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2024 276
TABLE 375 ELI LILLY AND COMPANY: COMPANY OVERVIEW 277
TABLE 376 ELI LILLY AND COMPANY: PRODUCTS OFFERED 279
TABLE 377 ELI LILLY AND COMPANY: PRODUCT APPROVALS, JANUARY 2021–APRIL 2024 279
TABLE 378 ELI LILLY AND COMPANY: DEALS, JANUARY 2021–APRIL 2024 280
TABLE 379 ELI LILLY AND COMPANY: EXPANSIONS, JANUARY 2021–APRIL 2024 280
TABLE 380 SANOFI: COMPANY OVERVIEW 282
TABLE 381 SANOFI: PRODUCTS OFFERED 283
TABLE 382 ASTRAZENECA: COMPANY OVERVIEW 285
TABLE 383 ASTRAZENECA: PRODUCTS OFFERED 286
TABLE 384 ASTRAZENECA: PRODUCT APPROVALS, JANUARY 2021–APRIL 2024 287
TABLE 385 JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.: COMPANY OVERVIEW 288
TABLE 386 JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.: PRODUCTS OFFERED 289
TABLE 387 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW 290
TABLE 388 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS IN PIPELINE 291
TABLE 389 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: DEALS,
JANUARY 2021–APRIL 2024 292
TABLE 390 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2024 292
TABLE 391 INNOVENT: COMPANY OVERVIEW 293
TABLE 392 INNOVENT: PRODUCTS IN PIPELINE 294
TABLE 393 INNOVENT: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2024 294
TABLE 394 PAIGE BIOPHARMACEUTICAL (SUZHOU) CO., LTD.: COMPANY OVERVIEW 295
TABLE 395 PAIGE BIOPHARMACEUTICAL (SUZHOU) CO., LTD.: PRODUCTS IN PIPELINE 295
TABLE 396 SCIWIND BIOSCIENCES CO., LTD.: COMPANY OVERVIEW 296
TABLE 397 SCIWIND BIOSCIENCES CO., LTD.: PRODUCTS IN PIPELINE 296
TABLE 398 SCIWIND BIOSCIENCES CO., LTD.: DEALS, JANUARY 2021–APRIL 2024 297
TABLE 399 SCIWIND BIOSCIENCES CO., LTD.: OTHER DEVELOPMENTS,
JANUARY 2021–APRIL 2024 297
TABLE 400 ZEALAND PHARMA A/S: COMPANY OVERVIEW 298
TABLE 401 ZEALAND PHARMA A/S: PRODUCTS IN PIPELINE 299
TABLE 402 ZEALAND PHARMA A/S: DEALS, JANUARY 2021–APRIL 2024 299
TABLE 403 ZEALAND PHARMA A/S: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2024 299
TABLE 404 BEIJING DONGFANG BAITAI BIOTECHNOLOGY: COMPANY OVERVIEW 300
TABLE 405 BEIJING DONGFANG BAITAI BIOTECHNOLOGY: PRODUCTS IN PIPELINE 300
LIST OF FIGURES
FIGURE 1 GLP-1 ANALOGUES MARKET SEGMENTATION 30
FIGURE 2 GLP-1 ANALOGUES MARKET: REGIONAL SEGMENTATION 30
FIGURE 3 RESEARCH DESIGN 33
FIGURE 4 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 35
FIGURE 5 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2023 36
FIGURE 6 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2023 36
FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS 37
FIGURE 8 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 38
FIGURE 9 CAGR PROJECTIONS: GLP-1 ANALOGUES MARKET, 2024–2032 39
FIGURE 10 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES IN GLP-1 ANALOGUES MARKET 40
FIGURE 11 DATA TRIANGULATION METHODOLOGY 41
FIGURE 12 GLP-1 ANALOGUES MARKET, BY PRODUCT, 2024 VS. 2032 (USD BILLION) 44
FIGURE 13 GLP-1 ANALOGUES MARKET SHARE, BY FORMAT, 2024 VS. 2032 (USD BILLION) 45
FIGURE 14 GLP-1 ANALOGUES MARKET SHARE, BY ROUTE OF ADMINISTRATION,
2024 VS. 2032 (USD BILLION) 45
FIGURE 15 GLP-1 ANALOGUES MARKET SHARE, BY INDICATION,
2024 VS. 2032 (USD BILLION) 46
FIGURE 16 GLP-1 ANALOGUES MARKET, BY END USER, 2024−2032 (USD BILLION) 46
FIGURE 17 GLP-1 ANALOGUES MARKET: GEOGRAPHICAL SNAPSHOT 47
FIGURE 18 IMPROVED EFFICACY OF GLP-1 DRUGS TO DRIVE MARKET GROWTH 48
FIGURE 19 DIABETES SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2023 49
FIGURE 20 OZEMPIC TO DOMINATE MARKET IN 2032 50
FIGURE 21 DIABETES INDICATIONS TO ACCOUNT FOR LARGEST MARKET SHARE IN 2023 51
FIGURE 22 HOME CARE SETTINGS TO DOMINATE THE MARKET IN 2032 51
FIGURE 23 US TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 52
FIGURE 24 GLP-1 ANALOGUES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 53
FIGURE 25 US: PREVALENCE OF INDICATIONS THAT MAY RESPOND TO GLP-1 DRUGS
(AS OF JANUARY 2024) 58
FIGURE 26 REVENUE SHIFT IN GLP-1 ANALOGUES MARKET 60
FIGURE 27 AVERAGE SELLING PRICE TREND, BY PRODUCT 60
FIGURE 28 PRODUCT PRICING, BY COUNTRY (2023–2024) 62
FIGURE 29 ADDITIONAL LAUNCHES OF GLP-1 DRUGS, 2025–2032 72
FIGURE 30 PHASE 3 PIPELINE, BY INDICATION 73
FIGURE 31 TOTAL NUMBER OF PATENTS GRANTED, 2014–2024 74
FIGURE 32 TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS,
2014–2024 74
FIGURE 33 VALUE CHAIN ANALYSIS: PRODUCT DEVELOPMENT AND MANUFACTURING PHASE CONTRIBUTES MAXIMUM VALUE 76
FIGURE 34 GLP-1 ANALOGUES MARKET: SUPPLY CHAIN ANALYSIS 78
FIGURE 35 GLP-1 ANALOGUES MARKET: ECOSYSTEM ANALYSIS 79
FIGURE 36 GLP-1 ANALOGUES MARKET: PORTER’S FIVE FORCES ANALYSIS 82
FIGURE 37 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF GLP-1 ANALOGUES, HOSPITALS 83
FIGURE 38 KEY BUYING CRITERIA FOR END USERS 84
FIGURE 39 NORTH AMERICA GLP-1 ANALOGUES MARKET SNAPSHOT 165
FIGURE 40 EUROPE: GLP-1 ANALOGUES MARKET SNAPSHOT 175
FIGURE 41 REVENUE ANALYSIS OF KEY PLAYERS IN GLP-1 ANALOGUES MARKET, 2021–2023 250
FIGURE 42 MARKET SHARE ANALYSIS OF KEY PLAYERS IN GLP-1 ANALOGUES MARKET, 2023 251
FIGURE 43 GLP-1 ANALOGUES MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2023 254
FIGURE 44 GLP-1 ANALOGUES MARKET: COMPANY EVALUATION MATRIX
(PLAYERS WITH PRODUCTS IN PIPELINE), 2023 256
FIGURE 45 GLP-1 ANALOGUES MARKET: COMPANY FOOTPRINT (KEY PLAYERS) 257
FIGURE 46 GLP-1 ANALOGUES MARKET: COMPANY FOOTPRINT (PLAYERS WITH PRODUCTS
IN PIPELINE) 258
FIGURE 47 GLP-1 ANALOGUES MARKET: COMPANY EVALUATION MATRIX
(STARTUPS/SMES), 2023 263
FIGURE 48 EV/EBITDA OF KEY VENDORS 266
FIGURE 49 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF
KEY VENDORS 266
FIGURE 50 GLP-1 ANALOGUES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS (ANTIDIABETIC GLP-1 ANALOGUES) 267
FIGURE 51 GLP-1 ANALOGUES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
(ANTI-OBESITY GLP-1 ANALOGUES) 268
FIGURE 52 NOVO NORDISK A/S: COMPANY SNAPSHOT 273
FIGURE 53 ELI LILLY AND COMPANY: COMPANY SNAPSHOT 278
FIGURE 54 SANOFI: COMPANY SNAPSHOT 283
FIGURE 55 ASTRAZENECA: COMPANY SNAPSHOT 286
FIGURE 56 JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.: COMPANY SNAPSHOT 289
FIGURE 57 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT 291
FIGURE 58 INNOVENT: COMPANY SNAPSHOT 293
FIGURE 59 ZEALAND PHARMA A/S: COMPANY SNAPSHOT 298
